Vergelijking

Icatibant vs. Triptorelin

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Onderzoek (overig)

CAS-nr.

138614-30-9

57773-63-4

Molecuulmassa

1304.52 g/mol

1311.45 g/mol

Halfwaardetijd

geen gegevens

3 h

Sequentie

geen gegevens

pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2

Werkingsmechanisme

Icatibant

Icatibant competitively blocks the bradykinin B2 receptor. Because bradykinin mediates the vascular permeability, swelling and pain typical of hereditary angioedema, the blockade interrupts the acute attack.

Triptorelin

Triptorelin binds with high affinity to the GnRH receptor in the pituitary. After initial stimulation of LH and FSH secretion (flare phase, about 1-2 weeks), receptor desensitisation follows with consecutive gonadotropin suppression. This results in a reversible chemical castration: in men testosterone, in women oestrogen suppression to the postmenopausal range.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Icatibant	Triptorelin
Duitsland	Op recept	Op recept
Verenigde Staten	Op recept	Op recept

Volledige vermeldingen

Icatibant

Volledige vermelding →

Triptorelin

Volledige vermelding →

Frequently asked questions

What is the difference between Icatibant and Triptorelin?: Icatibant is classified as "Onderzoek (overig)", while Triptorelin is classified as "Onderzoek (overig)". Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). Triptorelin: Synthetic decapeptide GnRH agonist with increased affinity over native gonadotropin-releasing hormone. FDA- and EMA-approved since the 1980s for prostate cancer, endometriosis and precocious puberty. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Icatibant or Triptorelin?: The highest available evidence level is "Humane RCT" for Icatibant and "Humane RCT" for Triptorelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Icatibant and Triptorelin in Germany and the United States?: Duitsland: Icatibant — Op recept, Triptorelin — Op recept. Verenigde Staten: Icatibant — Op recept, Triptorelin — Op recept. These are factual summaries with source and review date on the individual pages.

Country

Icatibant

Triptorelin

Duitsland

Op recept

Verenigde Staten

Op recept

Frequently asked questions

What is the difference between Icatibant and Triptorelin?

Icatibant is classified as "Onderzoek (overig)", while Triptorelin is classified as "Onderzoek (overig)". Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). Triptorelin: Synthetic decapeptide GnRH agonist with increased affinity over native gonadotropin-releasing hormone. FDA- and EMA-approved since the 1980s for prostate cancer, endometriosis and precocious puberty. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Icatibant or Triptorelin?

The highest available evidence level is "Humane RCT" for Icatibant and "Humane RCT" for Triptorelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Icatibant and Triptorelin in Germany and the United States?

Duitsland: Icatibant — Op recept, Triptorelin — Op recept. Verenigde Staten: Icatibant — Op recept, Triptorelin — Op recept. These are factual summaries with source and review date on the individual pages.